Deferiprone

Deferiprone
Clinical data
Trade names	Ferriprox
AHFS/Drugs.com	Monograph
MedlinePlus	a612016
License data	US DailyMed: Deferiprone;
Pregnancy; category	AU: D; ;
Routes of; administration	By mouth
ATC code	V03AC02 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; UK: POM (Prescription only) / P; US: WARNINGRx-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Metabolism	Glucuronidation
Elimination half-life	2 to 3 hours
Excretion	Kidney (75 to 90% in 24 hours)
Identifiers
	IUPAC name 3-hydroxy-1,2-dimethylpyridin-4(1H)-one;
CAS Number	30652-11-0 ;
PubChem CID	2972;
IUPHAR/BPS	7456;
DrugBank	DB08826 ;
ChemSpider	2866 ;
UNII	2BTY8KH53L;
KEGG	D07416 ;
ChEBI	CHEBI:68554 ;
ChEMBL	ChEMBL70927 ;
CompTox Dashboard (EPA)	DTXSID6040666 ;
ECHA InfoCard	100.157.470
Chemical and physical data
Formula	C7H9NO2
Molar mass	139.154 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C\1C(\O)=C(/N(/C=C/1)C)C;
	InChI InChI=1S/C7H9NO2/c1-5-7(10)6(9)3-4-8(5)2/h3-4,10H,1-2H3 ; Key:TZXKOCQBRNJULO-UHFFFAOYSA-N ;
	(what is this?) (verify)

Deferiprone, sold under the brand name Ferriprox among others, is a medication that chelates iron and is used to treat iron overload in thalassaemia major.^[5] It was first approved and indicated for use in treating thalassaemia major in 1994^[6] and had been licensed for use in the European Union for many years while awaiting approval in Canada and in the United States.^[5] On 14 October 2011, it was approved for use in the US under the FDA's accelerated approval program.^[7]^[8]

The most common side effects include red-brown urine (showing that iron is being removed through the urine), nausea (feeling sick), abdominal pain (stomach ache) and vomiting.^[9]^[7] Less common but more serious side effects are agranulocytosis (very low levels of granulocytes, a type of white blood cell) and neutropenia (low levels of neutrophils, a type of white blood cell that fights infections).^[9]^[7]

^ "Deferiprone (Ferriprox) Use During Pregnancy". Drugs.com. 30 March 2020. Retrieved 20 May 2020.
^ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
^ "Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Retrieved 7 April 2024.
^ "Ferriprox 100 mg/ml oral solution - Summary of Product Characteristics (SmPC)". (emc). 26 November 2019. Retrieved 20 May 2020.
^ ^a ^b Savulescu J (February 2004). "Thalassaemia major: the murky story of deferiprone". BMJ. 328 (7436): 358–9. doi:10.1136/bmj.328.7436.358. PMC 341373. PMID 14962851.
^ Staff. "Cipla's History". Cipla. Archived from the original on 27 October 2015.
^ ^a ^b ^c "FDA Approves Ferripox (deferiprone) to Treat Patients with Excess Iron in the Body". U.S. Food and Drug Administration (FDA) (Press release). 14 October 2011. Archived from the original on 10 October 2016. This article incorporates text from this source, which is in the public domain.
^ "Drug Approval Package: Ferriprox (deferiprone) Tablet NDA #021825". U.S. Food and Drug Administration (FDA). 30 November 2011. Retrieved 20 May 2020.
^ ^a ^b "Ferriprox EPAR". European Medicines Agency (EMA). Retrieved 20 May 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[Drugs.com_pregnancy-1] "Deferiprone (Ferriprox) Use During Pregnancy". Drugs.com. 30 March 2020. Retrieved 20 May 2020.

[FDA-AllBoxedWarnings-2] "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.

[3] "Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 4 May 2016. Retrieved 7 April 2024.

[4] "Ferriprox 100 mg/ml oral solution - Summary of Product Characteristics (SmPC)". (emc). 26 November 2019. Retrieved 20 May 2020.

[savulescu-5] Savulescu J (February 2004). "Thalassaemia major: the murky story of deferiprone". BMJ. 328 (7436): 358–9. doi:10.1136/bmj.328.7436.358. PMC 341373. PMID 14962851.

[6] Staff. "Cipla's History". Cipla. Archived from the original on 27 October 2015.

[FDA_PR-7] "FDA Approves Ferripox (deferiprone) to Treat Patients with Excess Iron in the Body". U.S. Food and Drug Administration (FDA) (Press release). 14 October 2011. Archived from the original on 10 October 2016. This article incorporates text from this source, which is in the public domain.

[FDA_approval-8] "Drug Approval Package: Ferriprox (deferiprone) Tablet NDA #021825". U.S. Food and Drug Administration (FDA). 30 November 2011. Retrieved 20 May 2020.

[Ferriprox_EPAR-9] "Ferriprox EPAR". European Medicines Agency (EMA). Retrieved 20 May 2020. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.

[1]

[3]

[4]

[2]

[5]

[6]

[7]

[8]

[9]